JAGX

Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing parenteral support needs in pediatric patients Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / October 21, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has been continuing to provide the company's novel crofelemer powder for oral solution for several weeks for the treatment of intestinal failure (IF) in an infant patient with GUCY2C mutation resulting in congenital sodium diarrhea (CSD). Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support (PS) with no significant clinical or laboratory abnormalities.

Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today provided an update in connection with the Company's previously announced special stock dividend (the "Special Stock Dividend"), which is payable on October 15, 2026, to holders of Jaguar common stock and certain outstanding warrants as of record on October 13, 2026, to announce that The Nasdaq Stock Market LLC ("Nasdaq") has indicated that the ex-dividend date for the Special Stock Dividend is October 16, 2026 (the "Ex-Dividend Date"). The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, targeting a mid-2027 NDA filing for MVID SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026) for the ongoing open-label pilot study of the company's crofelemer powder for oral solution in adult patients with Type 1 short bowel syndrome (T1SBS) with intestinal failure (SBS-IF). The abstract presented at ACG 2026, titled The Use of Crofelemer in Reducing Ostomy Output in Patients With Type 1 Short Bowel Syndrome: An Open Label Pilot Study, can be viewed by clicking here.

Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / October 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today issued a reminder that today, October 13, 2026, is the Record Date for the Company's special stock dividend (the "Special Stock Dividend"). As announced, Jaguar's Board of Directors declared a Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026.

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 A recent Rareatives article shares the story of a young child living with MVID, highlighting the importance of family perspectives, supportive communication, and collaboration with clinicians in addressing rare intestinal diseases SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi in the United Arab Emirates and is also sponsoring a panel discussion titled Intestinal Barrier Beyond Total Parenteral Nutrition (TPN) on October 30, 2026 at the meeting. Participants in the panel discussion include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's Chief Scientific Officer and Chair of the Scientific Advisory Board.

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.

A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.

Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day's action on the companies themselves rather than on any broader rotation.

Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn't selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Prescription Drug User Fee Act (PDUFA) for Mytesi ® (crofelemer delayed-release tablets) for the 2027 fiscal year. Mytesi is an FDA-approved prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and is currently commercialized in the U.S. by Future Pak, LLC.